Piramal Pharma Limited has officially notified stock exchanges about its upcoming board meeting scheduled for January 28, 2026, to review and approve the company's quarterly financial performance. The pharmaceutical company issued the intimation under Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Board Meeting Details

The board meeting will focus on considering and approving the unaudited financial results for both standalone and consolidated operations. The meeting covers the financial performance for the quarter and nine months ended December 31, 2025.

Trading Window Closure

In accordance with regulatory requirements, Piramal Pharma Limited has implemented a trading window closure for company securities. The trading window, which commenced closure on January 1, 2026, will remain closed until January 30, 2026, both days inclusive.

Regulatory Compliance

The company has formally notified both major Indian stock exchanges about the scheduled board meeting. BSE Limited, where the company trades under scrip code 543635, and National Stock Exchange of India Limited, where it trades under the symbol PPLPHARMA, have been informed through official communication dated January 16, 2026.

Company Secretary Tanya Sanish signed the official intimation, ensuring compliance with SEBI Listing Regulations. The notification follows standard corporate governance practices for listed pharmaceutical companies in India, providing investors and stakeholders with advance notice of material financial disclosures.

Piramal Pharma Limited has issued a postal ballot notice seeking shareholder approval for the appointment of Mr. Amit Soni as an Independent Director. The company announced the formal voting process through a regulatory filing under Regulation 30 of SEBI Listing Regulations.

Postal Ballot Details

Director Appointment Proposal

The Board has approved the appointment of Mr. Amit Soni (DIN: 05111144) as a Non-Executive Independent Director for a five-year term. The appointment requires shareholder approval through a special resolution as mandated under SEBI Listing Regulations.

About Amit Soni

Mr. Soni brings extensive investment experience to Piramal Pharma's board. As a Partner at CVC Capital, he established the firm's India operations and has led significant investments across multiple sectors.

Professional Background

Educational Qualifications

Voting Process

The company will conduct voting exclusively through remote e-voting, with no physical ballot forms being distributed. Members whose email addresses are registered with the company or depositories will receive the notice electronically. The postal ballot notice includes detailed instructions for accessing the NSDL e-voting platform.

Current Directorships

Mr. Soni currently serves on the boards of several companies including Cohizon Life Sciences Limited, CVC Advisers (India) Private Limited, and Irelia Sports India Private Limited. He also holds committee positions in statutory committees of these organizations.

The appointment aligns with the company's commitment to strengthening its board composition with experienced professionals who can contribute to strategic decision-making and corporate governance.